AP31969 Interaction Study in Healthy Subjects

This trial explores how two different drugs, carbamazepine (an anticonvulsant) and itraconazole (an antifungal), affect the body's handling of a new treatment called AP31969. Researchers aim to determine if these drugs alter the absorption and processing of AP31969. The trial consists of two parts: one tests carbamazepine, and the other tests itraconazole. It seeks healthy individuals in good physical and mental health. Participants should not have a history of certain health conditions or use specific medications or substances. As a Phase 1 trial, this research focuses on understanding how AP31969 works in people, offering participants the unique opportunity to be among the first to receive this new treatment.

Yes, you will need to stop taking any prescribed medications 30 days before joining the trial, except for hormonal contraceptives. Over-the-counter medications and supplements should be stopped 14 days before, except for acetaminophen, which is allowed up to 2 grams per day.

Studies have identified some safety concerns with carbamazepine. Patients have reported an increased risk of suicidal thoughts and behaviors, so a mental health check-up is advisable if possible. Carbamazepine can interact with many other medications, so caution is necessary when taking other drugs. Some individuals might experience skin reactions due to their genetic makeup.

Itraconazole also presents safety considerations. It can cause skin and eye irritation, and in rare cases, it has been linked to serious liver problems, including liver failure. It can interact with many other drugs, potentially leading to heart issues, such as irregular heartbeats.

Researchers are excited about AP31969 because it offers a novel approach compared to existing treatments that typically involve anticonvulsants or antifungal medications like carbamazepine and itraconazole alone. AP31969 is being tested for its potential to enhance the effects of these drugs through its unique mechanism of action that may improve their efficacy and safety profile. Unlike standard treatments that are primarily focused on their direct therapeutic effects, AP31969 could provide an innovative way to optimize these medications' performance, potentially leading to better outcomes for patients.

This trial will examine the interactions of AP31969 with carbamazepine and itraconazole in healthy subjects. Studies have shown that carbamazepine, which accelerates the breakdown of other medications, can reduce the effectiveness of drugs like edoxaban by about half. Therefore, when combined with AP31969, carbamazepine might decrease its effectiveness by lowering its concentration in the body. Conversely, research indicates that itraconazole can increase the levels of certain drugs by slowing their breakdown, potentially enhancing AP31969's effectiveness by maintaining higher active levels in the body. Understanding these interactions is crucial for assessing how AP31969 functions when taken with either carbamazepine or itraconazole in this trial.⁶⁷⁸⁹¹⁰